Eli Lilly ROE 1986-2025 | LLY

Current and historical return on equity (ROE) values for Eli Lilly (LLY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Eli Lilly ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2025-06-30 $13.80B $18.35B 87.91%
2025-03-31 $11.11B $15.85B 76.49%
2024-12-31 $10.59B $14.27B 76.84%
2024-09-30 $8.37B $14.32B 64.74%
2024-06-30 $7.34B $13.64B 60.31%
2024-03-31 $6.14B $12.90B 53.13%
2023-12-31 $5.24B $10.86B 46.99%
2023-09-30 $4.99B $11.31B 44.82%
2023-06-30 $6.50B $11.15B 59.91%
2023-03-31 $5.69B $11.30B 55.64%
2022-12-31 $6.25B $10.78B 63.96%
2022-09-30 $6.03B $10.17B 64.46%
2022-06-30 $5.69B $8.66B 64.63%
2022-03-31 $6.13B $9.46B 73.77%
2021-12-31 $5.58B $9.16B 72.31%
2021-09-30 $5.97B $7.95B 86.73%
2021-06-30 $6.07B $6.66B 98.76%
2021-03-31 $6.09B $7.10B 109.81%
2020-12-31 $6.19B $5.83B 135.46%
2020-09-30 $5.57B $5.00B 147.01%
2020-06-30 $5.62B $4.27B 164.90%
2020-03-31 $5.53B $3.20B 181.22%
2019-12-31 $8.32B $2.70B 287.28%
2019-09-30 $7.95B $3.46B 160.62%
2019-06-30 $7.84B $2.86B 102.93%
2019-03-31 $6.26B $2.57B 63.77%
2018-12-31 $3.23B $10.91B 25.22%
2018-09-30 $0.45B $14.15B 3.46%
2018-06-30 $-0.14B $11.62B -1.09%
2018-03-31 $1.12B $14.59B 8.12%
2017-12-31 $-0.20B $11.67B -1.49%
2017-09-30 $2.23B $14.96B 15.53%
2017-06-30 $2.45B $14.17B 16.88%
2017-03-31 $2.19B $14.10B 14.96%
2016-12-31 $2.74B $14.08B 18.44%
2016-09-30 $2.44B $15.62B 16.32%
2016-06-30 $2.47B $14.66B 16.57%
2016-03-31 $2.32B $15.03B 15.57%
2015-12-31 $2.41B $14.59B 16.20%
2015-09-30 $2.36B $15.24B 15.66%
2015-06-30 $2.06B $14.71B 13.14%
2015-03-31 $2.19B $14.95B 13.29%
2014-12-31 $2.39B $15.39B 13.78%
2014-09-30 $2.69B $17.68B 15.01%
2014-06-30 $3.39B $18.00B 19.14%
2014-03-31 $3.86B $18.35B 22.69%
2013-12-31 $4.68B $17.64B 28.95%
2013-09-30 $4.78B $16.90B 30.93%
2013-06-30 $4.91B $15.24B 32.17%
2013-03-31 $4.63B $14.96B 30.79%
2012-12-31 $4.09B $14.77B 27.28%
2012-09-30 $4.12B $16.06B 28.06%
2012-06-30 $4.03B $14.31B 27.92%
2012-03-31 $4.30B $14.82B 29.83%
2011-12-31 $4.35B $13.54B 30.61%
2011-09-30 $4.66B $15.06B 33.47%
2011-06-30 $4.73B $14.28B 35.65%
2011-03-31 $4.88B $13.93B 39.83%
2010-12-31 $5.07B $12.41B 44.56%
2010-09-30 $4.82B $12.41B 45.18%
2010-06-30 $4.45B $10.24B 44.40%
2010-03-31 $4.26B $10.46B 44.36%
2009-12-31 $4.33B $9.53B 48.48%
2009-09-30 $-0.22B $9.91B -2.61%
2009-06-30 $-1.62B $8.56B -17.66%
2009-03-31 $-1.82B $7.73B -16.98%
2008-12-31 $-2.07B $6.74B -16.53%
2008-09-30 $2.41B $13.74B 16.95%
2008-06-30 $3.80B $14.74B 27.12%
2008-03-31 $3.51B $14.91B 26.51%
2007-12-31 $2.95B $13.50B 23.84%
2007-09-30 $2.23B $12.95B 18.98%
2007-06-30 $2.18B $11.56B 18.49%
2007-03-31 $2.34B $11.53B 19.68%
2006-12-31 $2.66B $10.98B 22.35%
2006-09-30 $3.23B $13.06B 27.23%
2006-06-30 $3.15B $11.93B 27.53%
2006-03-31 $2.08B $11.69B 18.83%
2005-12-31 $1.98B $10.79B 17.98%
2005-09-30 $1.28B $11.38B 11.56%
2005-06-30 $1.24B $10.27B 11.23%
2005-03-31 $2.15B $11.60B 19.37%
2004-12-31 $1.81B $10.92B 16.73%
2004-09-30 $2.56B $11.31B 24.29%
2004-06-30 $2.52B $10.50B 24.99%
2004-03-31 $2.55B $10.56B 26.53%
2003-12-31 $2.56B $9.77B 27.93%
2003-09-30 $2.55B $9.49B 28.99%
2003-06-30 $2.52B $8.69B 29.68%
2003-03-31 $2.49B $8.73B 30.12%
2002-12-31 $2.71B $8.27B 33.87%
2002-09-30 $2.55B $8.26B 33.06%
2002-06-30 $2.43B $7.75B 32.53%
2002-03-31 $2.60B $7.70B 35.97%
2001-12-31 $2.78B $7.10B 39.96%
2001-09-30 $2.97B $7.37B 44.41%
2001-06-30 $3.18B $6.76B 49.96%
2001-03-31 $3.02B $6.59B 49.86%
2000-12-31 $3.06B $6.05B 52.54%
2000-09-30 $3.08B $6.06B 55.32%
2000-06-30 $3.03B $5.51B 57.59%
2000-03-31 $2.94B $5.66B 58.85%
1999-12-31 $2.72B $5.01B 56.71%
1999-09-30 $2.50B $4.87B 53.78%
1999-06-30 $2.29B $4.45B 50.13%
1999-03-31 $2.20B $4.86B 47.76%
1998-12-31 $2.10B $4.43B 45.65%
1998-09-30 $1.99B $4.51B 42.78%
1998-06-30 $1.93B $4.64B 41.73%
1998-03-31 $-0.30B $4.79B -6.40%
1997-12-31 $-0.38B $4.65B -7.58%
1997-09-30 $-0.47B $4.39B -8.63%
1997-06-30 $-0.51B $4.67B -8.73%
1997-03-31 $1.57B $6.57B 25.51%
1996-12-31 $1.52B $6.10B 25.54%
1996-09-30 $1.49B $6.03B 25.76%
1996-06-30 $2.31B $5.89B 40.71%
1996-03-31 $2.29B $5.85B 40.23%
1995-12-31 $2.29B $5.43B 40.32%
1995-09-30 $2.24B $5.49B 39.52%
1995-06-30 $1.33B $5.97B 23.65%
1995-03-31 $1.35B $5.84B 24.92%
1994-12-31 $1.29B $5.36B 24.80%
1994-09-30 $0.47B $5.32B 9.47%
1994-06-30 $0.45B $5.15B 8.90%
1994-03-31 $0.45B $4.94B 8.81%
1993-12-31 $0.48B $4.57B 9.31%
1993-09-30 $1.32B $5.47B 25.12%
1993-06-30 $0.75B $5.36B 14.69%
1993-03-31 $0.75B $5.22B 14.42%
1992-12-31 $0.71B $4.89B 13.64%
1992-09-30 $0.71B $5.00B 13.60%
1992-06-30 $1.28B $5.55B 24.65%
1992-03-31 $1.25B $5.31B 25.07%
1991-12-31 $1.32B $4.97B 27.17%
1991-09-30 $1.26B $4.86B 28.20%
1991-06-30 $1.22B $4.86B 29.59%
1991-03-31 $1.18B $4.69B 30.30%
1990-12-31 $1.13B $3.47B 30.19%
1990-09-30 $1.10B $3.46B 28.83%
1990-06-30 $1.05B $3.89B 27.27%
1990-03-31 $1.00B $4.11B 26.37%
1989-12-31 $0.94B $3.76B 26.05%
1989-09-30 $0.89B $3.68B 25.63%
1989-06-30 $0.85B $3.55B 25.25%
1989-03-31 $0.81B $3.43B 24.88%
1988-12-31 $0.76B $3.23B 23.70%
1988-09-30 $0.72B $3.24B 22.84%
1988-06-30 $0.70B $3.18B 22.57%
1988-03-31 $0.67B $3.21B 21.98%
1987-12-31 $0.64B $3.04B 21.49%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $495.141B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12